Juvenile Arthritis Data For Novartis' Ilaris Also Supports Role In Gouty Arthritis
This article was originally published in The Pink Sheet Daily
Novartis' canakinumab shows promise in the first of two Phase III studies in systemic juvenile idiopathic arthritis, a severe and apparently distinct form of juvenile arthritis.
You may also be interested in...
The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.
Arthritis Advisory Committee votes against approval of Novartis' biologic for treatment of gout attacks, citing the need for more data on long-term safety and retreatment, along with a narrower indication.
Eight years after Novartis AG launched the Novartis Institutes for Biomedical Research under Harvard Medical School cardiologist Mark Fishman and let him design a novel strategy for vetting early-stage projects, the company's Phase II success rate for new molecular entities has doubled.